The U.S. telehealth market size reached US$ 42.61 billion in 2024 and is anticipate to increase to US$ 52.76 billion in 2025. By 2034, the market is forecasted to achieve a value of around US$ 358.96 billion, growing at a CAGR of 23.84%.
Clinical Trials- Clinical trials in the U.S. telehealth sector, which gained momentum during the COVID-19 pandemic, leverage remote tools such as video visits, digital monitoring, and electronic data capture to enhance patient participation, accessibility, and engagement in research studies.
Regulatory Approvals- In the U.S., telehealth regulations are managed by multiple federal and state agencies, including CMS, FDA, and HHS, each overseeing different aspects. The COVID-19 pandemic led to the temporary relaxation of several telehealth rules, some of which, especially for behavioral and mental health, have now become permanent, while others continue to be reviewed and adjusted.
Patient Support and Services- U.S. telehealth patient support includes technical help, clinical guidance, and administrative assistance to ensure patients can access and navigate remote healthcare smoothly. These services address challenges like platform use, scheduling, and technology access. Key aspects involve educating patients on using telehealth tools, supporting those with limited digital skills or in underserved areas, and helping with insurance and billing, all aimed at improving patient experience and promoting equitable access to virtual care.
In January 2025, the U.S. Drug Enforcement Administration (DEA) introduced three new rules to make some temporary telemedicine flexibilities from the COVID-19 pandemic permanent, while also enhancing patient safety. These rules ensure telemedicine remains accessible, particularly for prescribing controlled medications to patients who have not previously had an in-person visit with a provider. DEA Administrator Anne Milgram emphasized that the goal is to improve access to needed medications while preventing misuse. The rules also require online telemedicine platforms to register with the DEA and support a nationwide Prescription Drug Monitoring Program (PDMP). Telemedicine visits without prescriptions, or for patients already seen in person, are not affected.
Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com
